市場調查報告書

多發性硬化症治療藥的全球市場:產業趨勢,佔有率,市場規模,成長性,機會,預測,2020年∼2025年

Multiple Sclerosis Therapies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025

出版商 IMARC Services Private Limited 商品編碼 967723
出版日期 內容資訊 英文 145 Pages
商品交期: 2-3個工作天內
價格
多發性硬化症治療藥的全球市場:產業趨勢,佔有率,市場規模,成長性,機會,預測,2020年∼2025年 Multiple Sclerosis Therapies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025
出版日期: 2020年10月16日內容資訊: 英文 145 Pages
簡介

全球多發性硬化症治療藥市場,從2014年到2019年緩慢成長。多發性硬化症(MS),是有引起脊髓和腦的神經細胞的去髓鞘化,神經軸突切斷,神經退化的可能性的慢性及發炎性的免疫媒介疾病,一般用的治療方法,有注射藥,口服藥,注射劑,肌肉鬆弛劑,抗憂鬱症藥,物理治療等。

市場擴大的原動力,是復發型多發性硬化症(RRMS),首發漸進型多發性硬化症(PPMS),次發性進展型多發性硬化症(SPMS),進展型復發型多發性硬化症(PRMS)的全球盛行率上升,老年人口的增加,創新的單株抗體,免疫調節劑,免疫抑制劑,干擾素的開發等要素。

本報告提供全球多發性硬化症治療藥市場調查,市場概要,各類醫藥品,醫藥品的各類型,各給藥途徑,各流通管道,各地區的分析,產業和價值鏈分析,價格分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 序文

第2章 調查範圍與手法

第3章 摘要整理

第4章 簡介

第5章 全球市場

  • 市場概要
  • 市場成果
  • COVID-19的影響

第6章 各類醫藥品的市場分析

  • 免疫調節劑
  • 免疫抑制劑

第7章 各醫藥品類型的市場分析

  • 生物製藥
  • 低分子藥

第8章 各給藥途徑的市場分析

  • 口服給藥
  • 注射
  • 靜脈注射

第9章 各流通管道的市場分析

  • 醫院的藥局
  • 零售藥局
  • 線上藥局

第10章 各地區的市場分析

  • 北美
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 南美
    • 巴西
    • 墨西哥
    • 其他
  • 中東、非洲

第11章 SWOT分析

第12章 價值鏈分析

第13章 波特的五力分析

第14章 價格分析

第15章 競爭情形

  • 市場結構
  • 主要企業
  • 主要企業的簡介
    • Abbvie Inc.
    • Bayer Aktiengesellschaft
    • Biogen Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche AG (Roche Holding AG)
    • GlaxoSmithKline Plc
    • Merck & Co. Inc.
    • Novartis AG
    • Sanofi S.A.
    • Teva Pharmaceutical Industries Ltd.
目錄
Product Code: SR1019N64_Report

The global multiple sclerosis therapies market experienced moderate growth during 2014-2019. Multiple sclerosis (MS) refers to a chronic and inflammatory immune-mediated condition that can cause demyelination, axonal transection and neurodegeneration of the nerve cells in the spinal cord and brain. Some of the commonly used therapies include the administration of injectable, oral and infused medicines, muscle relaxants, antidepressants and physical therapy. The injectable medication, such as Interferon-beta and Glatiramer acetate, are administered under the skin or into the muscle; oral medications include Dimethyl fumarate, Teriflunomide and Cladribine; and infusion treatments include Ocrelizumab, Natalizumab and Alemtuzumab, which are administered intravenously. These medicines aid in managing the symptoms to minimize the frequency of the relapses and control the heart rate and blood pressure of the patient.

The increasing prevalence of relapsing-remitting multiple sclerosis (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS) and progressive-relapsing MS (PRMS) across the globe, is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the market growth. Healthcare providers are widely using immunosuppressants that control autoimmune attacks and prevent relapses among patients suffering from MS. Additionally, various technological advancements, such as the development of innovative monoclonal bodies, immunomodulators, immunosuppressants and interferons for the effective treatment of MS, are acting as other major growth-inducing factors. Apart from this, governments of both the developed and emerging countries are launching campaigns to increase awareness regarding the available treatment alternatives among the masses, which, in turn, is creating a positive outlook for the market. Other factors, including extensive research and development (R&D) activities, along with the improvements in the healthcare infrastructure, are anticipated to drive the market further. Looking forward, IMARC Group expects the global multiple sclerosis therapies market to continue its moderate growth during the next five years.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global multiple sclerosis therapies market report, along with forecasts for growth at the global, regional and country level from 2020-2025. Our report has categorized the market based on region, drug, drug type, route of administration and distribution channel.

Breakup by Drug:

  • Immunomodulators
  • Copaxone
  • Avonex/Plegridy
  • Gilneya
  • Tysabri
  • Betaseron/Extavia
  • Tecifidera
  • Rebif
  • Ampyra
  • Immunosuppressants
  • Aubagio
  • Lemtrada
  • Ocrelizumab
  • Zinbryta

Breakup by Drug Type:

  • Biologic Drugs
  • Small Molecule Drugs

Breakup by Route of Administration:

  • Oral
  • Injectable
  • Intravenous

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

  • The report has also analysed the competitive landscape of the market with some of the key players being Abbvie Inc., Bayer Aktiengesellschaft, Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Sanofi S.A. and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

  • How has the global multiple sclerosis therapies market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global multiple sclerosis therapies market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global multiple sclerosis therapies market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Multiple Sclerosis Therapies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug

  • 6.1 Immunomodulators
    • 6.1.1 Market Trends
    • 6.1.2 Major Types
      • 6.1.2.1 Copaxone
      • 6.1.2.2 Avonex/Plegridy
      • 6.1.2.3 Gilneya
      • 6.1.2.4 Tysabri
      • 6.1.2.5 Betaseron/Extavia
      • 6.1.2.6 Tecifidera
      • 6.1.2.7 Rebif
      • 6.1.2.8 Ampyra
    • 6.1.3 Market Forecast
  • 6.2 Immunosuppressants
    • 6.2.1 Market Trends
    • 6.2.2 Major Types
      • 6.1.2.1 Aubagio
      • 6.1.2.2 Lemtrada
      • 6.1.2.3 Ocrelizumab
      • 6.1.2.4 Zinbryta
    • 6.2.3 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Biologic Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Small Molecule Drugs
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Injectable
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Intravenous
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospitals Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Online Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbvie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Bayer Aktiengesellschaft
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Biogen Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Bristol-Myers Squibb Company
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 F. Hoffmann-La Roche AG (Roche Holding AG)
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 SWOT Analysis
    • 15.3.6 GlaxoSmithKline Plc
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Merck & Co. Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Novartis AG
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Sanofi S.A.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Teva Pharmaceutical Industries Ltd.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Multiple Sclerosis Therapies Market: Major Drivers and Challenges
  • Figure 2: Global: Multiple Sclerosis Therapies Market: Sales Value (in Billion US$), 2014-2019
  • Figure 3: Global: Multiple Sclerosis Therapies Market: Breakup by Drug (in %), 2019
  • Figure 4: Global: Multiple Sclerosis Therapies Market: Breakup by Drug Type (in %), 2019
  • Figure 5: Global: Multiple Sclerosis Therapies Market: Breakup by Route of Administration (in %), 2019
  • Figure 6: Global: Multiple Sclerosis Therapies Market: Breakup by Distribution Channel (in %), 2019
  • Figure 7: Global: Multiple Sclerosis Therapies Market: Breakup by Region (in %), 2019
  • Figure 8: Global: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Billion US$), 2020-2025
  • Figure 9: Global: Multiple Sclerosis Therapies (Immunomodulators) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 10: Global: Multiple Sclerosis Therapies (Immunomodulators) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 11: Global: Multiple Sclerosis Therapies (Immunosuppressants) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 12: Global: Multiple Sclerosis Therapies (Immunosuppressants) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 13: Global: Multiple Sclerosis Therapies (Biologic Drugs) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 14: Global: Multiple Sclerosis Therapies (Biologic Drugs) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 15: Global: Multiple Sclerosis Therapies (Small Molecule Drugs) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 16: Global: Multiple Sclerosis Therapies (Small Molecule Drugs) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 17: Global: Multiple Sclerosis Therapies (Oral) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 18: Global: Multiple Sclerosis Therapies (Oral) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 19: Global: Multiple Sclerosis Therapies (Injectable) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 20: Global: Multiple Sclerosis Therapies (Injectable) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 21: Global: Multiple Sclerosis Therapies (Intravenous) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 22: Global: Multiple Sclerosis Therapies (Intravenous) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 23: Global: Multiple Sclerosis Therapies (Hospital Pharmacies) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 24: Global: Multiple Sclerosis Therapies (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 25: Global: Multiple Sclerosis Therapies (Retail Pharmacies) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 26: Global: Multiple Sclerosis Therapies (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 27: Global: Multiple Sclerosis Therapies (Online Pharmacies) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 28: Global: Multiple Sclerosis Therapies (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 29: North America: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 30: North America: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 31: United States: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 32: United States: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 33: Canada: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 34: Canada: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 35: Asia Pacific: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 36: Asia Pacific: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 37: China: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 38: China: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 39: Japan: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 40: Japan: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 41: India: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 42: India: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 43: South Korea: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 44: South Korea: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 45: Australia: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 46: Australia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 47: Indonesia: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 48: Indonesia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 49: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 50: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 51: Europe: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 52: Europe: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 53: Germany: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 54: Germany: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 55: France: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 56: France: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 57: United Kingdom: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 58: United Kingdom: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 59: Italy: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 60: Italy: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 61: Spain: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 62: Spain: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 63: Russia: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 64: Russia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 65: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 66: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 67: Latin America: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 68: Latin America: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 69: Brazil: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 70: Brazil: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 71: Mexico: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 72: Mexico: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 73: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 74: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 75: Middle East and Africa: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 76: Middle East and Africa: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 77: Global: Multiple Sclerosis Therapies Industry: SWOT Analysis
  • Figure 78: Global: Multiple Sclerosis Therapies Industry: Value Chain Analysis
  • Figure 79: Global: Multiple Sclerosis Therapies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Multiple Sclerosis Therapies Market: Key Industry Highlights, 2019 and 2025
  • Table 2: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Drug (in Million US$), 2020-2025
  • Table 3: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Drug Type (in Million US$), 2020-2025
  • Table 4: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Route of Administration (in Million US$), 2020-2025
  • Table 5: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Distribution Channel in Million US$), 2020-2025
  • Table 6: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Region (in Million US$), 2020-2025
  • Table 7: Global: Multiple Sclerosis Therapies Market Structure
  • Table 8: Global: Multiple Sclerosis Therapies Market: Key Players